Molecular testing in locally advanced NSCLC: Implications for targeted therapies versus IO
Se-Hoon Lee and Tejas Patil explore how molecular testing guides treatment decisions with immunotherapy in locally advanced NSCLC by reviewing their own clinical case studies and the supporting clinical trial data.
The role of molecular testing in treatment decisions

Discussion: The role of PD-L1 testing when treating unresectable NSCLC

Molecular testing priorities and recent data

Discussion: How does mutation status influence treatment approach?
